Biomarkers in Patients With Pneumonia

January 13, 2020 updated by: Duan jun, Chongqing Medical University

Biomarkers and Associated Outcomes in Patients With Pneumonia

To identifying biomarkers in patients with pneumonia

Study Overview

Status

Unknown

Conditions

Detailed Description

The aim of this study is to identify the biomarkers in patients with pneumonia. These biomarkers can distinguish community-acquired pneumonia, hospital-acquired pneumonia, severe pneumonia, bacterial infection, virus infection and fungal infection. Furthermore, these biomarkers can identify the efficacy of treatment in patients with different interventions.

Study Type

Observational

Enrollment (Anticipated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
      • Chongqing, China
        • Recruiting
        • The First Affiliated Hospital of Chongqing Medical University
        • Contact:
          • Jun Duan, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

patients with pneumonia

Description

Inclusion Criteria: Healthy patients without any diseases -

Exclusion Criteria:Age less than 18 years

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
mortality
Time Frame: From diagnosis of pneumonia to discharge from hospital or up to 90 days, whichever came first
Mortality is defined the patient died in hospital.
From diagnosis of pneumonia to discharge from hospital or up to 90 days, whichever came first

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
severe pneumonia
Time Frame: From diagnosis of pneumonia to discharge from hospital or up to 90 days, whichever came first
The pneumonia deteriorated and reached the criteria of severe pneumonia. Severe pneumonia was diagnosed according to the guideline published by ATS.
From diagnosis of pneumonia to discharge from hospital or up to 90 days, whichever came first
initial treatment failure
Time Frame: From diagnosis of pneumonia to discharge from hospital or up to 90 days, whichever came first
Initial treatment failure means the patients' condition progressively deteriorated although comprehensive treatment was administrated. As a result, the treatment should be changed or the patient required admission to ICU.
From diagnosis of pneumonia to discharge from hospital or up to 90 days, whichever came first

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chongqing Medical University

Investigators

  • Principal Investigator: Jun Duan, MD, First Affiliated Hospital of Chongqing Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2018

Primary Completion (Anticipated)

December 31, 2020

Study Completion (Anticipated)

December 31, 2020

Study Registration Dates

First Submitted

July 26, 2018

First Submitted That Met QC Criteria

August 2, 2018

First Posted (Actual)

August 8, 2018

Study Record Updates

Last Update Posted (Actual)

January 14, 2020

Last Update Submitted That Met QC Criteria

January 13, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ChongqingMU3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Data sharement should be contact with us.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pneumonia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe